Clinical & Behavioral Guidelines

Reference: The Asthma Clinical Practice Guideline, titled “Guidelines for the Diagnosis and Management of Asthma” is a National Guideline developed by the National Heart, Lung and Blood Institute as part of the National Asthma Education and Prevention Program. The Expert Panel Report 3 was initially published in July 2007. The key components of the guideline include the definition, diagnosis of asthma, managing asthma long term, managing exacerbations and patient education.

Clinical Indicators:

1. The percentage of members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications of 0.50 or greater during the measurement year.
   (SOURCE: HEDIS® 2018, Volume 2, Technical Specifications)
2. The percentage of members 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period.
   1. The percentage of members who remained on an asthma controller medication for at least 75% of their treatment period.
   (SOURCE: HEDIS® 2018, Volume 2, Technical Specifications)

Links:

• National Asthma Education and Prevention Program Expert Panel Report 3

For guidelines regarding:

• ADHD
•  Alcohol/Substance Use
• Anxiety
• Bipolar
• Depression
• Adolescent Depression
• Post-partum Depression
• Eating Disorders
• OCD
• Prescribing Opioids for Chronic Conditions
• PTSD
• Schizophrenia
• Substance Abuse

Please reference the Beacon Health Options Clinical Practice Guidelines at: https://www.beaconhealthoptions.com/providers/beacon/handbook/clinical-practice-guidelines/

Reference:A National Guideline developed by the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease-2016, Global Initiative for Chronic Obstructive Lung Disease (GOLD).

Clinical Indicators:

1. Percentage of COPD exacerbations for members 40 years and older who had an acute inpatient discharge or ED visit between January 1- November 30 of the measurement year and who were dispensed a systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event.
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)
2. Percentage of COPD exacerbations for members 40 years and older who had an acute inpatient discharge or ED visit between January 1- November 30 of the measurement year and who were dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event.
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)

Links:

• COPD Global Strategy

Reference: Update to 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for Management of Heart Failure NEW recommendation: patients at increased risk stage A HF, the optimal blood pressure in those w/HTN should be <130/80mm Hg, per new randomized control trial data, page 24.

Clinical Indicators:

1. The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)
2. The percentage of males 21-75 and females 40-75 years of age during the measurement year who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and who the following criteria. The following rates are reported:
   1. Received statin therapy: Members who were dispensed at least one high or moderate-intensity statin medication during the measurement year.
   2. Statin Adherence 80%: Members who remained on a high or moderate-intensity statin medication for at least 80% of the treatment period.
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)

Links:

• Management of Adults with Elevated Cholesterol
• Management of Patients with Heart Failure
• Management of Patients with CAD

Reference: No changes to The Journal of Clinical and Applied Research and Education Diabetes Care, American Diabetes Association Standards of Medical Care in Diabetes – Dated January 2017

Clinical Indicators:

1. The percentage of members 18–75 years of age with diabetes (type 1 and type 2) who had an HbA1c poor control (>9%).
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)
2. The percentage of members 18–75 years of age with diabetes (type 1 and type 2) who had an eye exam performed.
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)

Links:

• American Diabetes Association, Diabetes Care

Reference: The HIV Clinical Practice Guideline titled, “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents” is a national guideline, following the recommendations by the U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). This guideline describes the best clinical practices based on available knowledge and a consensus of experts as of July 14, 2016. The guideline outlines General Care, Antiretroviral Lab Testing and Therapy, Care of Adolescents and Women with HIV/AIDS, drug interactions, HIV-related preventative care and ancillary services. It also provides available HIV Resources.

Last Updated March 27, 2018: Initiation of Antiretroviral Therapy

• A new subsection was added to discuss the data on the efficacy and feasibility of immediate antiretroviral therapy (ART) initiation on the day of HIV diagnosis.

Clinical Indicators:

1. Number of HIV+ individuals with at least one outpatient visit in the past 12 months.
2. Percentage of enrollees age 18 and older with a diagnosis of Human Immunodeficiency Virus (HIV) who had a HIV viral load test during the measurement year. (HRSA)
3. Percentage of individuals with pharmacy claims for HIV medications in the past 12 months with an 80% medication possession ratio.

Links:

• Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

Reference: The hypertension clinical practice guideline titled “Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee” (JNC 8), follows the recommendations of Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-8, 2013). This document discusses best practices in the diagnosis, monitoring and treatment of hypertension and is evidence-based.

Clinical Indicators:

1. Percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled during the measurement year based on the following criteria:
   1. Members 18-59 years of age whose BP was <140/90 mm Hg.
   (SOURCE: HEDIS^® 2018, Vol. 2, Technical Specifications)

Links:

• Evidence-Based Guideline for the Management of High Blood Pressure in Adults

Reference: The “Clinical Practice Guidelines for Quality Palliative Care” 2013, 4th Edition, was formed through the collaborative efforts of palliative care leaders from across the United Stated in 2001 to form the National Consensus Project for Quality Palliative Care with representation from five major hospice and palliative care organizations at the time: The American Academy of Hospice and Palliative Medicine, The Center to Advanced Palliative Care, The Hospice and Palliative Nurses Association, Last Acts Partnership, and the National Hospice and Palliative Care Organization. Key components of the guideline describe core concepts and structures for quality palliative care, including eight domains of practice. The 2013 edition was produced through a consensus process among leadership professional hospice and palliative care organizations. In this revision, the emphasis is on continuity, consistency and quality of care.

Clinical Indicators:

1. Evidence of advanced care planning as documented through either administrative data or medical record review.
2. Number of members identified with palliative care.
3. At least one pain assessment during the measurement year, as documented through either administrative data or medical record review.

Links:

• National Consensus Project, Palliative Care

Reference: West Virginia Family Health adopts The American Academy of Pediatric Dentistry: Guideline on Periodicity of Examination, Preventive Dental Services, Anticipatory Guidance/Counseling, and Oral Treatment for Infants, Children, and Adolescents, 2013.

The American Academy of Pediatric Dentistry (AAPD) intends for this guideline to help practitioners make clinical decisions concerning preventive oral health interventions, including anticipatory guidance and preventive counseling, for infants, children and adolescents. Since each child is unique, these recommendations are designed for the care of children who have no contributing medical conditions and are developing normally. Please note, these recommendations will need to be modified for children with special health care needs or if disease or trauma manifests variations from normal. In addition, the American Academy of Pediatric Dentistry (AAPD) emphasizes the importance of very early professional intervention and continuity of care based on the individualized needs of the child. It is recommended that children receive their first dental exam by 12 months of age.

West Virginia Oral Health Coalition (WVOHC) formed in 2011, to improve oral health in children and adolescents since issues were identified with dental care. Children and adolescents with Medicaid dental coverage were more likely to experience tooth decay than those with CHIP or private insurance (2012-2013). Tooth decay was evident in 56% of third graders and 21% had untreated cavities (2013-2014); children and adolescents had dental sealants on their permanent molar teeth only 19% of the time.

The guideline is relative to WVFH’s child population (ages 0-21) which represents about 24% of the total Medicaid population.The 2014 Burden of Oral Disease in West Virginia Report indicatesWest Virginia children had significant experience with tooth decay. A statewide survey from the 2010-2011 school year showed that 34% of the universal Pre-K population had experience with caries (tooth decay) and 21% of the children had untreated dental decay. The report also indicated that tooth decay is largely preventable and childhood years are the perfect time for preventive measures. Dental visits in the early ages can help.

New guideline for 2018. Latest Version AAPD 2013, no changes for 2017.

Clinical Indicators:

1. The percentage of members 2–20 years of age who had at least one dental visit during the measurement year.
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)
2. The percentage of dental exams in children ages 2-3.
   (SOURCE: HEDIS® 2018, Vol. 2, Technical Specifications)

Links:

• AAPD
• WVOHC

Reference: "West Virginia Family Health follows the Centers for Disease Control and Prevention, recommended Adult Immunization Schedule-United States, 2017. The Adult Immunization Schedule has been approved by ACIP, ACOG, ACP & AAFP.

Clinical Indicators:

1. The percentage of women 50-74 years of age who had a mammogram to screen for breast cancer. (Source: HEDIS® 2018, Vol. 2, Technical Specifications, BCS)
2. The percentage of members 50-75 years of age who had appropriate screening for colorectal cancer. (Source: HEDIS® 2018, Vol. 2, Technical Specifications, CCS)

Links:

• Immunization
• Adult Guidelines Recommended
• Vaccinations Indicated for Adults Based on Medical and Other Indications

Reference: West Virginia Family Health must provide comprehensive health screenings according to the West Virginia Periodicity Schedule and corresponds to the American Academy of Pediatrics’ Bright Futures Schedule for Health Supervision of Infants, Children and Adolescents. Last update: February 2017

Clinical Indicators:

1. The percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (HepB), one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and nine separate combination rates.
   (SOURCE: HEDIS® 2018, Volume 2, Technical Specifications)
2. The percentage of enrolled members 12–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.
   (SOURCE: HEDIS® 2018, Volume 2, Technical Specifications)
3. The percentage of members who turned 15 months old during the measurement year and who had the following number of well-child visits with a PCP during their first 15 months of life:
   1. No well-child visits.
   2. One well-child visit.
   3. Two well-child visits.
   4. Three well-child visits.
   5. Four well-child visits.
   6. Five well-child visits.
   7. Six or more well-child visits.
   (SOURCE: HEDIS® 2018, Volume 2, Technical Specifications)

Links:

• CDC Immunization Schedule 2018
• Bright Futures Recommendations Preventive Health Care
• CDC Child Development

Reference: Obesity prevention messages should be targeted at all families, starting at the time of the child's birth (Strong Recommendation, High Quality Evidence) (Barlow & Expert Committee, 2007).

Clinical Indicators:

1. Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents, ages 3- 17 years.
2. The percentage of members 3-17 years of age who had an outpatient visit with a PCP or OB/GYN and had evidence of following:
   1. BMI percentile documentation
   2. Counseling for nutrition
   3. Counseling for physical activity

Links:

• CDC Childhood Overweight and Obesity
• American Academy of Pediatrics

Reference: Updated ACOG Bulletins from 2016 and 2017, ACOG News Room Practice Advisories and ACOG Committee Opinions

Clinical Indicators:

1. The percentage of Medicaid deliveries between November 6 of the year prior to the measurement year and November 5 of the measurement year that had the following number of expected prenatal visits:
   • 21% of expected visits
   • 21%-40% of expected visits
   • 41%-60% of expected visits * 61%-80% of expected visits
   • 81% of expected visits
   (Source: HEDIS® 2018 Vol. 2, Technical Specifications, FPC)
2. The percentage of deliveries of live births between November 6 of the year prior to the measurement year and November 5 of the measurement year.
   • Timeliness of Prenatal Care. The percentage of deliveries that received a prenatal care visit as a member of the organization in the first trimester or within 42 days of enrollment in the organization.
   • Postpartum Care. The percentage of deliveries that had a postpartum visit on or between 21 and 56 days after delivery.
   (Source: HEDIS® 2018, Vol. 2, Technical Specifications, PPC)

Links:

• https://www.acog.org/About-ACOG/News-Room/Practice-Advisories
• https://www.acog.org/Resources-And-Publications/Committee-Opinions-List

• Guidelines may not apply to every patient or clinical situation; some variation from guidelines is expected. Provider judgment and knowledge of an individual patient supersedes clinical guidelines.
• Guidelines do not determine insurance coverage of health care services or products. Coverage decisions are based on member eligibility, contractual benefits, and determination of medical necessity.